HTATSF1 and cancer: In addition, HTATSF1 truncations or mutations, although less common than amplification, increase the sensitivity of breast and lung tumor cells to PARPi and platinum drug, suggesting potential synthetic lethality strategies for HTATSF1-deficient or -mutant cancers.